Operating income for the second quarter of the fiscal year ending June 2026 has been revised upward from 5,270 million yen to 5,717 million yen, an increase of 8.5%. Full-year operating income has also been revised upward from 10,500 million yen to 11,050 million yen, a 5.2% increase.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"9267","jir_company_name":"Genky DrugStores Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-01-22","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/01\/9267-20260122-01.pdf","jir_short_summary":"Operating income for the second quarter of the fiscal year ending June 2026 has been revised upward from 5,270 million yen to 5,717 million yen, an increase of 8.5%. Full-year operating income has also been revised upward from 10,500 million yen to 11,050 million yen, a 5.2% increase.","jir_summary":"### Summary of Earnings Guidance Revision\nThe consolidated earnings guidance for the second quarter and full fiscal year ending June 2026 has been revised. For the second quarter, net sales are nearly on plan, with expected increases of approximately 8% in operating income, ordinary income, and net income attributable to owners of parent. For the full year, net sales have been slightly lowered, but operating income and net income are forecasted to increase by around 5%. Cost control on labor and improvement in gross profit margin contributed in the first half.\n\n### Revision of Second Half Plan and Future Outlook\nThe number of store openings in the second half has been reduced from 45 to 41, decreasing the net sales plan by approximately 690 million yen. The main causes are rising construction costs and tight construction schedules. The number of store closures remains as planned at 3 stores, expecting a net increase of 58 stores for the full year. The company continues to aim for 100 store openings annually and will strengthen the store development division. While increased interest expenses impact ordinary income, efforts to improve rental income are also underway.","jir_financial_highlights":"Net Sales (2nd Quarter): 109,261 million yen (Compared to previous forecast +0.0%)\nOperating Income (2nd Quarter): 5,717 million yen (Compared to previous forecast +8.5%)\nNet Income Attributable to Owners of Parent (2nd Quarter): 4,020 million yen (Compared to previous forecast +8.7%)\nNet Sales (Full Year): 221,200 million yen (Compared to previous forecast -0.3%)\nOperating Income (Full Year): 11,050 million yen (Compared to previous forecast +5.2%)\nNet Income Attributable to Owners of Parent (Full Year): 7,850 million yen (Compared to previous forecast +4.7%)","jir_category":"","jir_hashtags":"#GenkyDrugStores, #EarningsGuidanceRevision, #JapaneseStocks","jir_key_figures":"2nd Quarter Net Sales: 109,261 million yen (Compared to previous forecast +0.0%)\n2nd Quarter Operating Income: 5,717 million yen (Compared to previous forecast +8.5%)\nFull Year Net Income Attributable to Owners of Parent: 7,850 million yen (Compared to previous forecast +4.7%)","jir_meta_title":"Genky DrugStores Revises Earnings Guidance for June 2026 Fiscal Year with 8.5% Increase in 2nd Quarter Operating Income","jir_meta_description":"Genky DrugStores Co., Ltd. has revised its consolidated earnings guidance for the second quarter and full fiscal year ending June 2026. Operating income is projected to increase by 8.5% in the second quarter and 5.2% for the full year, alongside a partial review of store opening plans.","jir_og_title":"Genky DrugStores Revises Earnings Guidance Expecting Increase in Operating Income","jir_og_description":"Revised earnings guidance for the fiscal year ending June 2026. Second quarter operating income up 8.5% from previous forecast. Store opening adjustment also announced.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9174,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"earnings_guidance","footnotes":""},"sector":[],"importance":[],"class_list":["post-20416","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n